Asia Pacific in vitro diagnostics (IVD) market will grow by 7.8% annually with a total addressable market cap of $303,673.6 million over 2022-2031, driven by the increasing prevalence of chronic diseases along with the growing geriatric population, burgeoning demand for automation in diagnostics, the rising development of condition-specific treatment and booming awareness regarding personalized medicines, emergence of minimally invasive and non-invasive diagnostics tools & techniques, the rising healthcare expenditure, and rise in the demand for POC testing.
Highlighted with 35 tables and 64 figures, this 138-page report "Asia Pacific In Vitro Diagnostics (IVD) Market 2021-2031 by Product (Instruments & Devices, Reagents & Kits, Software & Services), Technology (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics), Sample Type (Blood, Mucus, Urine), Application (Infectious Diseases, Diabetes, Cancer/Oncology), End User (Diagnostic Labs, Hospitals and Clinics, Homecare, POC), and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific in vitro diagnostics (IVD) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific in vitro diagnostics (IVD) market in every aspect of the classification from perspectives of Product, Technology, Sample Type, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Instruments & Devices
o Disposable IVD Devices
o Reusable IVD Devices
• Reagents & Kits
• Software & Services
Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Clinical Chemistry
• Molecular Diagnostics
• Immuno Diagnostics
• Hematology
• Tissue Diagnostics
• Microbiology
• Coagulation and Hemostasis
• Urinalysis
• Other Technologies
By Sample Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood
• Mucus
• Urine
• Other Sample Types
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Infectious Diseases
• Diabetes
• Cancer/Oncology
• Cardiology
• Autoimmune Disease
• Nephrology
• Drug Testing
• HIV/AIDS
• Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Diagnostic Laboratories
• Hospitals and Clinics
• Homecare Settings
• Point-of-Care (POC) Settings
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Application and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories, Inc.
Agilent Technologies, Inc.
Arkray Inc.
Becton, Dickinson and Company
Biomerieux SA
Bio-Rad Laboratories Inc.
Danaher Corporation
DiaSorin SpA (Luminex Corporation)
Epic Systems Corporation
F. Hoffmann-La Roche Ltd.
Genpact Limited
Grifols SA
IBM Corporation
Mckesson Corporation
Ortho Clinical Diagnostics Inc.
Qiagen NV
Quest Diagnostics Inc.
Quidel Corporation
Roche Diagnostics
Siemens Healthineers
Sysmex Corporation
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter's Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product 43
3.1 Market Overview by Product 43
3.2 Instruments & Devices 45
3.2.1 Disposable IVD Devices 46
3.2.2 Reusable IVD Devices 47
3.3 Reagents & Kits 48
3.4 Software & Services 49
4 Segmentation of Asia Pacific Market by Technology 50
4.1 Market Overview by Technology 50
4.2 Clinical Chemistry 52
4.3 Molecular Diagnostics 53
4.4 Immuno Diagnostics 54
4.5 Hematology 55
4.6 Tissue Diagnostics 56
4.7 Microbiology 57
4.8 Coagulation and Hemostasis 58
4.9 Urinalysis 59
4.10 Other Technologies 60
5 Segmentation of Asia Pacific Market by Sample Type 61
5.1 Market Overview by Sample Type 61
5.2 Blood 63
5.3 Mucus 64
5.4 Urine 65
5.5 Other Sample Types 66
6 Segmentation of Asia Pacific Market by Application 67
6.1 Market Overview by Application 67
6.2 Infectious Diseases 69
6.3 Diabetes 79
6.4 Cancer/Oncology 80
6.5 Cardiology 81
6.6 Autoimmune Disease 82
6.7 Nephrology 83
6.8 Drug Testing 84
6.9 HIV/AIDS 85
6.10 Other Applications 86
7 Segmentation of Asia Pacific Market by End User 87
7.1 Market Overview by End User 87
7.2 Diagnostic Laboratories 89
7.3 Hospitals and Clinics 90
7.4 Homecare Settings 91
7.5 Point-of-Care (POC) Settings 92
7.6 Other End Users 93
8 Asia-Pacific Market 2021-2031 by Country 94
8.1 Overview of Asia-Pacific Market 94
8.2 Japan 97
8.3 China 100
8.4 Australia 102
8.5 India 104
8.6 South Korea 106
8.7 Rest of APAC Region 108
9 Competitive Landscape 110
9.1 Overview of Key Vendors 110
9.2 New Product Launch, Partnership, Investment, and M&A 113
9.3 Company Profiles 114
Abbott Laboratories, Inc. 114
Agilent Technologies, Inc. 116
Arkray Inc. 117
Becton, Dickinson and Company 118
Biomerieux SA 119
Bio-Rad Laboratories Inc. 120
Danaher Corporation 121
DiaSorin SpA (Luminex Corporation) 122
Epic Systems Corporation 123
F. Hoffmann-La Roche Ltd. 124
Genpact Limited 125
Grifols SA 126
IBM Corporation 127
Mckesson Corporation 128
Ortho Clinical Diagnostics Inc. 129
Qiagen NV 130
Quest Diagnostics Inc. 131
Quidel Corporation 132
Roche Diagnostics 133
Siemens Healthineers 134
Sysmex Corporation 135
Thermo Fisher Scientific Inc. 136
RELATED REPORTS 137
Executive Summary
Azoth Analytics has released a research report titled "Global Infectious Disease In vitro Diagnostics Market (2024 Edition)" which provides a complete analysis of the Global Infectious Disease In vitro Diagnostics industry in terms of market segmentation By Technology ...
The In Vitro Diagnostics (IVD) Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufact...
The In - Vitro ADME Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufactur...
Asia Pacific cutting tools market will grow by 6.0% annually with a total addressable market cap of $163.03 billion over 2024-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for powe...
Asia Pacific paper machine clothing (PMC) market will grow by 5.3% annually with a total addressable market cap of $7.27 billion over 2024-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking p...
Asia Pacific endoscopy devices market will grow by 7.7% annually with a total addressable market cap of $150.27 billion over 2024-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic c...
Asia Pacific digital health and wellness market will grow by 20.8% annually with a total addressable market cap of $3,072.0 billion over 2024-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphon...
Asia Pacific connected healthcare device market will grow by 21.1% annually with a total addressable market cap of $495.3 billion over 2024-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetrat...
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...